Product Code: DIMI1740
DelveInsight's 'Hereditary Angioedema-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the Hereditary Angioedema (HAE), historical and forecasted epidemiology as well as the Hereditary Angioedema (HAE) market trends in the United States, the EU4 (Germany, France, Italy, Spain) and the United Kingdom, Japan, and China.
The Hereditary Angioedema (HAE) market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted 7MM+China Hereditary Angioedema (HAE) market size from 2019 to 2032. The Report also covers current Hereditary Angioedema (HAE) treatment practice, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geography Covered:
- The United States
- The EU4 (Germany, France, Italy, Spain) and the United Kingdom
- Japan
- China
Study Period: 2019-2032
Hereditary Angioedema (HAE) Disease Understanding and Treatment Algorithm
Hereditary Angioedema (HAE) Overview
Hereditary Angioedema (HAE) is a rare genetic disorder that predisposes an individual to develop vasogenic edema. This genetic disorder is caused by the deficiency in functional C1 inhibitor (C1-INH) that results in recurrent attacks of localized subcutaneous or mucosal edema, most commonly affecting the skin, intestines, upper respiratory tract, and oropharynx.
Clinical manifestations include abrupt onset swelling around the eyes, face, and extremities; pain abdomen (because of bowel edema) and laryngeal edema leading to hoarseness of voice, breathing difficulty, and occasionally death.
Hereditary Angioedema (HAE) Diagnosis
Early detection and diagnosis of HAE before the onset of clinical symptoms are critical for appropriate treatment, preserving patients' quality of life, and even the first attack of laryngeal edema can be fatal.
Diagnosis is made through a careful evaluation of clinical symptoms and family history and is confirmed using laboratory testing. Clinical symptoms of recurrent abdominal pain or edema without associated urticaria should prompt suspicion of HAE, particularly in patients with a positive family history.
Continued in the report…..
Hereditary Angioedema (HAE) Treatment
Therapeutic strategies focus on the reversal and/or prevention of attacks, reduction of morbidity and mortality, and improvement in the quality of life. There are two approaches to treatment: on-demand treatment of acute attacks and prophylactic treatment, both short and long-term.
On-demand treatment
The World Allergy Organization strongly recommends early treatment of HAE-C1-INH attacks with C1-INH concentrate, icatibant, or ecallantide, as tranexamic acid or androgens are ineffective for acute attacks.
Prophylactic treatment
- Short-term prophylaxis: HAE patients should receive short-term prophylaxis with C1-INH concentrate before it may induce an attack, e.g., surgical and dental procedures or invasive medical interventions.
- Long-term prophylaxis: Long-term prophylaxis aims to reduce the frequency and severity of HAE attacks.
Continued in the report…..
Hereditary Angioedema (HAE) Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Diagnosed Prevalent Cases of Hereditary Angioedema (HAE), Type-specific Diagnosed Prevalent Cases of Hereditary Angioedema (HAE), Gender-specific Diagnosed Prevalent Cases of Hereditary Angioedema (HAE), and Age-specific Diagnosed Prevalent Cases of Hereditary Angioedema (HAE) in the 7MM+China covering the United States, the EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, Japan, and China from 2019 to 2032.
Key Findings
- Total diagnosed prevalent cases of HAE in the 7MM+China was found to be 14,375 approximately in 2021, which might increase by the end of 2032. These cases are expected to increase at a considerable CAGR during study period (2019-2032).
- Among 7MM+China, the United States has the highest diagnosed prevalent cases of HAE with 7,614 cases in 2021.
- Among the European countries, the UK had the highest diagnosed prevalent population of HAE, with approximately 1,348 cases, followed by Germany, which had 1,266 diagnosed prevalent population in 2021. On the other hand, Spain and Italy had the lowest and equal number of diagnosed prevalent population as approximately 942 cases in 2021.
- The type-specific diagnosed prevalent cases of HAE is categorized into Type I, Type II, and HAE with normal C1-INH (Type III). Among these, Type I HAE accounted for the highest cases in the 7MM+China as estimated to be 12,345 in 2021.
- The diagnosed prevalent cases of HAE in the 7MM+China varied according to gender, with prevalent cases higher in females than males.
- Based on age segmented as =17 years, 17-65 years, and =65 years, a higher percentage of diagnosed prevalent cases were observed in the age group 17-65 years in all the 7MM+China countries were approximately 11,312 in 2021, which anticipated to rise during the forecasted period (2022-2032).
- Japan accounted for approximately 462 diagnosed prevalent cases of HAE in the year 2021 which are expected to decrease during the forecasted period (2022-2032).
- The total diagnosed prevalent cases of HAE in the China is anticipated to rise from estimated 563 cases in 2021 at a considerable CAGR for the study period (2019-2032).
Hereditary Angioedema (HAE) Epidemiology
The epidemiology segment also provides the Hereditary Angioedema (HAE) epidemiology data and findings across the United States, the EU4 (Germany, France, Italy, Spain) and the United Kingdom, Japan, and China.
Hereditary Angioedema (HAE) Drug Chapters
The drug chapter segment of the Hereditary Angioedema (HAE) report encloses the detailed analysis of HAE marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the HAE clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug, and the latest news and press releases.
Hereditary Angioedema (HAE) Marketed Drugs for Treatment
FIRAZYR: Shire/Takeda
FIRAZYR (Icatibant) is a selective, competitive BK B2 receptor antagonist indicated for treating acute attacks of HAE in adults aged 18 years and older. FIRAZYR is supplied as a single-use, prefilled syringe for SC administration.
Hereditary Angioedema (HAE) Marketed Prophylactic Drugs
ORLADEYO (berotralstat): BioCryst Ireland Limited
ORLADEYO (berotralstat) is a targeted oral prophylactic therapy for preventing swelling attacks associated with HAE in adults and pediatric patients aged 12 and older. This once-daily, small-molecule drug is the first orally bioavailable prophylactic treatment for HAE attacks, having completed a Phase III clinical trial (meeting its primary endpoint).
Hereditary Angioedema (HAE) Emerging Drugs for Treatment
Sebetralstat (KVD900): KalVista Pharmaceuticals
Sebetralstat/KVD900 is an oral plasma kallikrein (KLKB1) inhibitor developed by KalVista Pharmaceuticals as a therapeutic option for early use upon the onset of HAE attacks. An easy oral administration combined with its rapid uptake and encouraging safety profile makes KVD900 a potential candidate to offer HAE patients an effective and convenient treatment option to treat attacks at the earliest stages before the symptoms advance.
Hereditary Angioedema (HAE) Emerging Prophylactic Drugs
Garadacimab (CSL312): CSL Behring
Garadacimab is designated as an orphan medicine for treating HAE in the US by the FDA and the European Union. The positive results from its clinical trial show that garadacimab can become a transformative first-in-class therapy for people living with HAE.
Products detail in the report…
List of products to be continued in the report…
Hereditary Angioedema (HAE) Market Outlook
While there is no cure for HAE, there are many ways to prevent or subdue swelling attacks. Several HAE-specific agents are currently available, including attenuated androgens; while regional availability, regulatory approvals, and/or cost barriers may prevent access to some of these medications, other less proven therapies may have a role, including antifibrinolytics and fresh frozen plasma.
The market overall has been segmented into two treatment strategies commonly used for HAE: on-demand therapies, which are taken to minimize the severity of angioedema symptoms and resolve symptoms as quickly as possible. Long-term prophylaxis of attacks reduces disease burden; short-term (or periprocedural) prophylaxis treatment is taken before activities are known to trigger attacks.
Key Findings
- The total market size of HAE in the 7MM+China was approximately USD 2,152 million in 2021. Market is expected to increase by 2032 at a decent CAGR.
- Among all the 7MM+China, the US consistently captured the highest market with approximately USD 1,769 million in 2021, which is expected to grow during the forecasted period (2022-2032).
- In 2021, EU4 and the UK countries captured an estimated USD 347 million, which is expected to rise by 2032.
- The expected launch of potential therapy may increase market size in the coming years, assisted by an increase in the diagnosed prevalent population of Hereditary Angioedema.
- Upcoming therapy such as Garadacimab, Donidalorsen has the potential to create a significant positive shift in the Hereditary Angioedema (HAE) market size.
The United States Market Outlook
This section provides the total Hereditary Angioedema (HAE) market size and market size by therapies in the United States.
The EU4 and the UK Market Outlook
The total Hereditary Angioedema (HAE) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total Hereditary Angioedema (HAE) market size and market size by therapies in Japan are provided.
China Market Outlook
The total Hereditary Angioedema (HAE) market size and market size by therapies in China are provided.
Hereditary Angioedema (HAE) Drugs Uptake
This section focuses on the rate of uptake of the potential drugs recently launched in the Hereditary Angioedema (HAE) market or expected to get launched in the market during the study period 2019-2032. The analysis covers the Hereditary Angioedema (HAE) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows, the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Hereditary Angioedema (HAE) Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stages also analyze key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Hereditary Angioedema (HAE) emerging therapies.
Reimbursement Scenario in Hereditary Angioedema (HAE)
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
Competitive Intelligence Analysis
We perform competitively and market Intelligence analysis of the Hereditary Angioedema (HAE) market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report:
- The report covers the descriptive overview of Hereditary Angioedema (HAE), explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
- Comprehensive insight has been provided into the Hereditary Angioedema (HAE) epidemiology and treatment.
- Additionally, an all-inclusive account of both the current and emerging therapies for Hereditary Angioedema (HAE) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of the Hereditary Angioedema (HAE) market; historical and forecasted is included in the report, covering the 7MM+China drug outreach.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM+China Hereditary Angioedema (HAE) market.
Report Highlights:
- The robust pipeline with novel MOA and oral ROA and increasing diagnosed prevalence will positively drive the Hereditary Angioedema (HAE) market.
- The companies and academics are working to assess challenges and seek opportunities that could influence Hereditary Angioedema (HAE) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Major players are involved in developing therapies for Hereditary Angioedema. The launch of emerging therapies will significantly impact the Hereditary Angioedema (HAE) market.
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Hereditary Angioedema (HAE) Report Insights
- Patient Population
- Therapeutic Approaches
- Hereditary Angioedema (HAE) Pipeline Analysis
- Hereditary Angioedema (HAE) Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Hereditary Angioedema (HAE) Report Key Strengths
- 11-Years Forecast
- The 7MM+China Coverage
- Hereditary Angioedema (HAE) Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Hereditary Angioedema (HAE) Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- SWOT analysis
Key Questions
Market Insights:
- What was the Hereditary Angioedema (HAE) market share (%) distribution in 2019 and how it would look like in 2032?
- What would be the Hereditary Angioedema (HAE) total market size as well as market size by therapies across the 7MM+China during the forecast period (2022-2032)?
- What are the key findings pertaining to the market across the 7MM+China and which country will have the largest Hereditary Angioedema (HAE) market size during the forecast period (2022-2032)?
- At what CAGR, the Hereditary Angioedema (HAE) market is expected to grow at the 7MM+China level during the forecast period (2022-2032)?
- What would be the Hereditary Angioedema (HAE) market outlook across the 7MM+China during the forecast period (2022-2032)?
- What would be the Hereditary Angioedema (HAE) market growth till 2032 and what will be the resultant market size in the year 2032?
- How would the future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What is the disease risk, burden, and unmet needs of Hereditary Angioedema?
- What is the historical Hereditary Angioedema (HAE) patient pool in the United States, the EU4 (Germany, France, Italy, Spain) and the UK, Japan, and China?
- What would be the forecasted patient pool of Hereditary Angioedema (HAE) at the 7MM+China level?
- What will be the growth opportunities across the 7MM+China with respect to the patient population pertaining to Hereditary Angioedema?
- Out of the above-mentioned countries, which country would have the highest population of Hereditary Angioedema (HAE) during the forecast period (2022-2032)?
- At what CAGR the population is expected to grow across the 7MM+China during the forecast period (2022-2032)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
- What are the current options for the treatment of Hereditary Angioedema (HAE) along with the approved therapy?
- What are the current treatment guidelines for the treatment of Hereditary Angioedema (HAE) in the US and Europe?
- What are the Hereditary Angioedema (HAE) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
- How many companies are developing therapies for the treatment of Hereditary Angioedema (HAE)?
- How many emerging therapies are in the mid-stage and late stages of development for the treatment of Hereditary Angioedema (HAE)?
- What are the key collaborations (Industry-Industry, Industry-Academia), mergers and acquisitions, licensing activities related to the Hereditary Angioedema (HAE) therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Hereditary Angioedema (HAE) and their status?
- What are the key designations that have been granted for the emerging therapies for Hereditary Angioedema?
- What are the 7MM+China historical and forecasted market of Hereditary Angioedema?
Reasons to buy:
- The report will help in developing business strategies by understanding trends shaping and driving Hereditary Angioedema (HAE).
- To understand the future market competition in the Hereditary Angioedema (HAE) market.
- Organize sales and marketing efforts by identifying the best opportunities for Hereditary Angioedema (HAE) in the US, Europe (Germany, Spain, Italy, and France) and the United Kingdom, Japan, and China.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for the Hereditary Angioedema (HAE) market.
- To understand the future market competition in the Hereditary Angioedema (HAE) market.
Table of Contents
1. Key Insights
2. Report Introduction
3. Hereditary Angioedema Market Overview at a Glance
- 3.1. Market Share (%) Distribution of HAE by Therapies in 2019
- 3.2. Market Share (%) Distribution of HAE by Therapies in 2032
4. Executive Summary of Hereditary Angioedema
5. Key Events
6. Hereditary Angioedema (HAE): Disease Overview
- 6.1. Introduction of HAE
- 6.2. Types of HAE
- 6.3. Cause of HAE
- 6.4. Genetics of HAE
- 6.5. Pathophysiologic and Immunologic Features of HAE
- 6.5.1. Mechanisms of Edema Formation
- 6.6. Risk Factors of HAE
- 6.7. Symptoms of HAE
- 6.8. Clinical Presentation of HAE
- 6.9. Diagnosis of HAE
- 6.9.1. Differential and delayed diagnosis
- 6.9.2. Diagnostic algorithm
- 6.9.3. Diagnosis Guidelines
- 6.9.3.1. US HAEA Medical Advisory Board: Guidelines for the Management of HAE
- 6.9.3.2. The International World Allergy Organization / European Academy of Allergy and Clinical Immunology Guideline for the Management of HAE
- 6.9.3.3. The Japanese Association for Complement Research: Guideline for HAE
- 6.10. Treatment of HAE
- 6.10.1. Treatment Algorithm
- 6.10.2. Treatment Guidelines
- 6.10.2.1. US HAEA Medical Advisory Board: Guidelines for the Management of HAE
- 6.10.2.2. The International World Allergy Organization / European Academy of Allergy and Clinical Immunology Guideline for the Management of HAE
- 6.10.2.3. The Japanese Association for Complement Research: Guideline for HAE
- 6.10.2.4. AAAAI Allergy and Asthma Medication Guide
- 6.10.2.5. China Medical Tribune: Guidelines for the Diagnosis and Treatment of Rare Diseases-HAE
7. Epidemiology and Patient Population of HAE
- 7.1. Key Findings
- 7.2. Methodology of Epidemiology
- 7.3. Assumptions and Rationale: The 7MM+ China
- 7.4. Total Diagnosed Prevalent Cases of HAE in 7MM +China
- 7.5. The United States
- 7.5.1. Total Diagnosed Prevalent Cases of HAE in the US
- 7.5.2. Type-specific Diagnosed Prevalent Cases of HAE in the US
- 7.5.3. Gender-specific Diagnosed Prevalent Cases of HAE in the US
- 7.5.4. Age-specific Diagnosed Prevalent Cases of HAE in the US
- 7.6. EU-4 Countries and the UK
- 7.6.1. Germany
- 7.6.1.1. Total Diagnosed Prevalent Population of HAE
- 7.6.1.2. Type-specific Diagnosed Prevalent Cases of HAE
- 7.6.1.3. Gender-Specific Diagnosed Prevalent Population of HAE
- 7.6.1.4. Age-specific Diagnosed Prevalent Population of HAE
- 7.6.2. France
- 7.6.2.1. Total Diagnosed Prevalent Population of HAE
- 7.6.2.2. Type-specific Diagnosed Prevalent Cases of HAE
- 7.6.2.3. Gender-Specific Diagnosed Prevalent Population of HAE
- 7.6.2.4. Age-specific Diagnosed Prevalent Population of HAE
- 7.6.3. Italy
- 7.6.3.1. Total Diagnosed Prevalent Population of HAE
- 7.6.3.2. Type-specific Diagnosed Prevalent Cases of HAE
- 7.6.3.3. Gender-Specific Diagnosed Prevalent Population of HAE
- 7.6.3.4. Age-specific Diagnosed Prevalent Population of HAE
- 7.6.4. Spain
- 7.6.4.1. Total Diagnosed Prevalent Population of HAE
- 7.6.4.2. Type-specific Diagnosed Prevalent Cases of HAE
- 7.6.4.3. Gender-Specific Diagnosed Prevalent Population of HAE
- 7.6.4.4. Age-specific Diagnosed Prevalent Population of HAE
- 7.6.5. The UK
- 7.6.5.1. Total Diagnosed Prevalent Population of HAE
- 7.6.5.2. Type-specific Diagnosed Prevalent Cases of HAE
- 7.6.5.3. Gender-Specific Diagnosed Prevalent Population of HAE
- 7.6.5.4. Age-specific Diagnosed Prevalent Population of HAE
- 7.7. Japan Epidemiology
- 7.7.1. Total Diagnosed Prevalent Cases of HAE in Japan
- 7.7.2. Type-specific Diagnosed Prevalent Cases of HAE in Japan
- 7.7.3. Gender-specific Diagnosed Prevalent Cases of HAE in Japan
- 7.7.4. Age-specific Diagnosed Prevalent Cases of HAE in Japan
- 7.8. China Epidemiology
- 7.8.1. Total Diagnosed Prevalent Cases of HAE in China
- 7.8.2. Type-specific Diagnosed Prevalent Cases of HAE in China
- 7.8.3. Gender-specific Diagnosed Prevalent Cases of HAE in China
- 7.8.4. Age-specific Diagnosed Prevalent Cases of HAE in China
8. Patient Journey
9. Marketed Drugs for Treatment
- 9.1. Key Cross Competition
- 9.2. FIRAZYR: Shire/Takeda
- 9.2.1. Product description
- 9.2.2. Regulatory milestones
- 9.2.3. Other development activities
- 9.2.4. Clinical development
- 9.2.5. Clinical trials information
- 9.2.6. Safety and efficacy
- 9.2.7. Product profile
- 9.3. KALBITOR: Shire/Takeda
- 9.3.1. Product description
- 9.3.2. Regulatory milestones
- 9.3.3. Other development activities
- 9.3.4. Clinical development
- 9.3.5. Clinical trials information
- 9.3.6. Safety and efficacy
- 9.3.7. Product profile
- 9.4. BERINERT: CSL Behring
- 9.4.1. Product description
- 9.4.2. Regulatory milestones
- 9.4.3. Other developmental activities
- 9.4.4. Clinical development
- 9.4.5. Clinical trials information
- 9.4.6. Safety and Efficacy
- 9.4.7. Product profile
- 9.5. RUCONEST: Pharming Group
- 9.5.1. Product description
- 9.5.2. Regulatory milestones
- 9.5.3. Other developmental activities
- 9.5.4. Clinical development
- 9.5.5. Clinical trials information
- 9.5.6. Safety and efficacy
- 9.5.7. Product profile
10. Marketed Prophylactic Drugs
- 10.1. Key Cross Competition
- 10.2. ORLADEYO (berotralstat): BioCryst Ireland Limited
- 10.2.1. Product description
- 10.2.2. Regulatory milestones
- 10.2.3. Other developmental activities
- 10.2.4. Clinical development
- 10.2.5. Clinical trials information
- 10.2.6. Safety and efficacy
- 10.2.7. Product profile
- 10.3. CINRYZE: Shire/Takeda
- 10.3.1. Product description
- 10.3.2. Regulatory milestones
- 10.3.3. Other development activities
- 10.3.4. Clinical development
- 10.3.5. Clinical trials information
- 10.3.6. Safety and efficacy
- 10.3.7. Product profile
- 10.4. TAKHZYRO: Shire/Takeda/Dyax Corp
- 10.4.1. Product description
- 10.4.2. Regulatory milestones
- 10.4.3. Other development activities
- 10.4.4. Clinical development
- 10.4.5. Clinical trials information
- 10.4.6. Safety and efficacy
- 10.4.7. Product profile
- 10.5. HAEGARDA/ BERINERT 2000,3000: CSL Behring
- 10.5.1. Product description
- 10.5.2. Regulatory milestones
- 10.5.3. Other developmental activities
- 10.5.4. Clinical development
- 10.5.5. Clinical trials information
- 10.5.6. Safety and efficacy
- 10.5.7. Product profile
11. Emerging Drugs for Treatment
- 11.1. Key Cross Competition
- 11.2. Sebetralstat (KVD900): KalVista Pharmaceuticals
- 11.2.1. Drug description
- 11.2.2. Other developmental activities
- 11.2.3. Clinical development
- 11.2.4. Clinical trials information
- 11.2.5. Safety and efficacy
- 11.2.6. Product profile
- 11.2.7. Analysts' views
- 11.3. NTLA-2002: Intellia Therapeutics
- 11.3.1. Drug description
- 11.3.2. Other developmental activities
- 11.3.3. Clinical development
- 11.3.4. Clinical trials information
- 11.3.5. Safety and efficacy
- 11.3.6. Product profile
- 11.3.7. Analysts' views
- 11.4. BMN 331: BioMarin Pharmaceutical
- 11.4.1. Drug description
- 11.4.2. Other developmental activities
- 11.4.3. Clinical development
- 11.4.4. Clinical trials information
- 11.4.5. Product Profile
- 11.4.6. Analysts' views
12. Emerging Prophylactic Drugs
- 12.1. Key Cross Competition
- 12.2. Garadacimab (CSL312): CSL Behring
- 12.2.1. Drug description
- 12.2.2. Other developmental activities
- 12.2.3. Clinical development
- 12.2.4. Clinical trials information
- 12.2.5. Safety and efficacy
- 12.2.6. Product profile
- 12.2.7. Analysts' views
- 12.3. Donidalorsen (IONIS-PKK-LRx): Ionis Pharmaceuticals, Inc.
- 12.3.1. Drug description
- 12.3.2. Other developmental activities
- 12.3.3. Clinical development
- 12.3.4. Clinical trials information
- 12.3.5. Safety and efficacy
- 12.3.6. Product profile
- 12.3.7. Analysts' views
- 12.4. STAR-0215: Astria Therapeutics, Inc.
- 12.4.1. Drug description
- 12.4.2. Other developmental activities
- 12.4.3. Clinical development
- 12.4.4. Clinical trials information
- 12.4.5. Product profile
- 12.4.6. Analysts' views
- 12.5. PHA-121: Pharvaris Netherlands B.V.
- 12.5.1. Drug description
- 12.5.2. Other developmental activities
- 12.5.3. Clinical development
- 12.5.4. Clinical trials information
- 12.5.5. Safety and efficacy
- 12.5.6. Product profile
- 12.5.7. Analysts' views
13. Hereditary Angioedema: 7MM+China Market Analysis
- 13.1. Key Findings
- 13.2. Market Methodology
- 13.3. Market Outlook
- 13.4. Key Market Forecast Assumptions
- 13.5. Attribute Analysis
- 13.6. Market Size of HAE in 7MM+China
- 13.7. Market Size of HAE by Therapies in the 7MM+China
- 13.8. The US Market Size
- 13.8.1. Total Market Size of HAE in the US
- 13.8.2. Market size of HAE by therapies
- 13.9. Market Size of HAE in EU4 and the UK
- 13.9.1. Germany
- 13.9.1.1. Total Market Size of HAE
- 13.9.1.2. Market Size of HAE by Therapies
- 13.9.2. France
- 13.9.2.1. Total Market Size of HAE
- 13.9.2.2. Market Size of HAE by Therapies
- 13.9.3. Italy
- 13.9.3.1. Total Market Size of HAE
- 13.9.3.2. Market Size of HAE by Therapies
- 13.9.4. Spain
- 13.9.4.1. Total Market Size of HAE
- 13.9.4.2. Market Size of HAE by Therapies
- 13.9.5. The UK
- 13.9.5.1. Total Market Size of HAE
- 13.9.5.2. Market Size of HAE by Therapies
- 13.10. Japan Market Size
- 13.10.1. Total Market Size of HAE in Japan
- 13.10.2. Market Size of HAE by Therapies
- 13.11. China Market Size
- 13.11.1. Total Market Size of HAE in China
- 13.11.2. Market Size of HAE by China
14. Unmet Needs
15. SWOT Analysis
16. Key Opinion Leaders' Views
17. Market Access and Reimbursement
18. Appendix
- 18.1. Bibliography
- 18.2. Acronyms and Abbreviations
- 18.3. Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight